Four-year survival in patients (pts) undergoing liver surgery after neoadjuvant triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-CET) for previously treated and unresectable liver metastases from kras wt colorectal cancer (LM-CRC) (European trial OPTILIV, NCT00852228).

Françis Lévi ,Mohamed Hebbar,Pasquale F Innominato,Salvatore Tumolo,Denis Castaing,Céline Lepère,Michel Ducreux,Mohamed Bouchahda,Abdoulaye Karaboué,Philippe Rougier,Rosine Guimbaud,Denis Smith ,Stéphanie Truant ,Valérie Boige ,Carlos Carvalho ,C Focan ,René Adam

doi:10.1200/jco.2014.32.15_suppl.3589

Four-year survival in patients (pts) undergoing liver surgery after neoadjuvant triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-CET) for previously treated and unresectable liver metastases from kras wt colorectal cancer (LM-CRC) (European trial OPTILIV, NCT00852228).

Françis Lévi , Mohamed Hebbar + Show 15 more

https://doi.org/10.1200/jco.2014.32.15_suppl.3589

Copy DOI

Export

Save

Cite

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2014
Citations: 2

Affiliation: Inserm, Hôpital Paul-Brousse, Hôpital Claude Huriez, Azienda Ospedaliera Santa Maria Degli Angeli, Hôpital Européen Georges-Pompidou, Hôpital Européen, Institut Gustave Roussy, Hôpital Purpan, Hôpital Saint-André, Centre Hospitalier Universitaire de Lille, Hospital Prof. Dr. Fernando Fonseca, Clinique Saint-Joseph

#Undergoing Liver Surgery #Intravenous Cetuximab #Hepatic Artery Infusion #Unresectable Liver Metastases #Four-year Survival #Survival In Patients #Colorectal Cancer #Prior Chemo #European Trial #Artery Infusion

Abstract
Full-Text
Similar Papers

Abstract

Listen

3589 Background: IV chemotherapy (chemo) downsizes LM-CRC in most pts. Yet less than 15% of those with previously unresectable LM and prior chemo undergo successful complete macroscopic LM resectio...

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

Four-year survival in patients (pts) undergoing liver surgery after neoadjuvant triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-CET) for previously treated and unresectable liver metastases from kras wt colorectal cancer (LM-CRC) (European trial OPTILIV, NCT00852228).